KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to $9.0 million.

  • Arbutus Biopharma's Share-based Compensation fell 41.53% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 19.32%. This contributed to the annual value of $9.0 million for FY2024, which is 3.39% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Share-based Compensation of $9.0 million as of FY2024, which was down 3.39% from $9.3 million recorded in FY2023.
  • Over the past 5 years, Arbutus Biopharma's Share-based Compensation peaked at $9.3 million during FY2023, and registered a low of $6.2 million during FY2020.
  • Over the past 3 years, Arbutus Biopharma's median Share-based Compensation value was $9.0 million (recorded in 2024), while the average stood at $8.5 million.
  • In the last 5 years, Arbutus Biopharma's Share-based Compensation dropped by 9.38% in 2020 and then rose by 29.50% in 2023.
  • Over the past 5 years, Arbutus Biopharma's Share-based Compensation (Yearly) stood at $6.2 million in 2020, then rose by 4.27% to $6.4 million in 2021, then increased by 11.80% to $7.2 million in 2022, then grew by 29.50% to $9.3 million in 2023, then decreased by 3.39% to $9.0 million in 2024.